HCPCS Level II · Drugs administered other than oral method
J9021Injection, asparaginase, recombinant, (rylaze), 0.1 mg
✓ Active
Source: CMS HCPCS quarterly update, October 2026. Page updated September 29, 2026.
About J9021
J9021 is an HCPCS Level II code in the J series (drugs administered other than oral method), describing injection, asparaginase, recombinant, (rylaze), 0.1 mg.
It was added to HCPCS effective 01/01/2022.
Its Medicare coverage code is "C", meaning coverage is left to the Medicare contractor's judgment.
Details
- Short description
- Inj, aspara, rylaze, 0.1 mg
- Date added
- 01/01/2022
- Action effective
- 01/01/2022
- BETOS
- O1D
Related J90xx codes
- J9000Injection, doxorubicin hydrochloride, 10 mg
- J9003Leuprolide injectable (camcevi etm), 1 mg
- J9011Injection, datopotamab deruxtecan-dlnk, 1 mg
- J9015Injection, aldesleukin, per single use vial
- J9017Injection, arsenic trioxide, 1 mg
- J9022Injection, atezolizumab, 10 mg
- J9023Injection, avelumab, 10 mg
- J9024Injection, atezolizumab, 5 mg and hyaluronidase-tqjs
- J9025Injection, azacitidine, 1 mg
- J9026Injection, tarlatamab-dlle, 1 mg
- J9027Injection, clofarabine, 1 mg
- J9028Injection, nogapendekin alfa inbakicept-pmln, for intravesical use, 1 microgram
Common questions about J9021
Is HCPCS J9021 still valid?
- Yes. J9021 is active in the CMS October 2026 HCPCS file.
Does Medicare cover J9021?
- Its coverage code is "C": coverage is left to the Medicare contractor's judgment. Check the local coverage determination for your region.